Floatz logo

Nivestim

Gestational Trophoblastic Neoplasm

Fred Hutchinson Cancer Centerprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Gestational Trophoblastic Neoplasm cohort.

Asset / SponsorPhaseRating
Amifostine
Gynecologic Oncology Group
Phase 3B
Alemtuzumab
Fred Hutchinson Cancer Center
Phase 2B
Moxifloxacin
OHSU Knight Cancer Institute
Phase 3B
Ondansetron
Fred Hutchinson Cancer Center
Phase 2B
Prednisone
Fred Hutchinson Cancer Center
Phase 2B

View all 25 →

Same molecule, other indications

Nivestim is also rated in:

Burkitt lymphomaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
neutropeniaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →